Allergies News and Research

Latest Allergies News and Research

GSK places a batch of AS03 adjuvanted H1N1 vaccine on hold

Following reports from Canada's Public Health Agency that six patients had suffered allergic reactions after receiving the shot, GlaxoSmithKline plc has voluntarily placed a hold on a single batch of the AS03 adjuvanted H1N1 vaccine Arepanrix in Canada as a precautionary measure.

4 Dec 2009

PRP shows strong potential for accelerated healing of dental implant procedures

An exciting treatment gaining acceptance in orthopedics and sports medicine, called platelet-rich plasma therapy (PRP), is showing strong potential for accelerated healing of dental implant procedures, according to a prominent dental researcher and editor of the Journal of Oral Implantology.

4 Dec 2009

Initial positive data from Amira Pharmaceuticals' Phase 1 clinical study of AM461 DP2 antagonist

Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM461, the Company's second oral selective antagonist of the DP2 (also known as CRTH2) receptor.

3 Dec 2009

Cielo MedSolutions, DrFirst partner to provide a comprehensive e-prescribing solution

Cielo MedSolutions today announced a new partnership with DrFirst to provide comprehensive e-prescribing functionality to practices using the company's Cielo Clinic clinical quality management system. The fully integrated e-prescribing solution will enable customers to improve prescribing safety and medical practice efficiency.

3 Dec 2009

NIDA funds proposed 'seek and treat' strategy in the fight against HIV/AIDS

Dr. Julio Montaner - Director, British Columbia Centre for Excellence in HIV/AIDS (BC-CfE), and President, International AIDS Society - congratulated Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH), for taking a leadership role in the evaluation of the "Seek and Treat" strategy originally developed at the BC-CfE.

3 Dec 2009

NHLBI awards new federal grant to improve the quality of stored transfusion blood

A new, $2.8 million, four-year federal grant will support researchers at the University of Pittsburgh School of Medicine and their collaborators at Wake Forest University as they study why the quality of stored transfusion blood degrades over time and how to address the problem.

3 Dec 2009

Kalbitor drug approved by FDA

The U.S. Food and Drug Administration approved Kalbitor (ecallantide) on Dec. 1 to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition known as hereditary angioedema (HAE).

2 Dec 2009

Neogen announces acquisition of BioKits food safety business of San Diego

Neogen Corporation announced today that it has acquired the BioKits food safety business of San Diego, Calif.-based Gen-Probe Incorporated ( GPRO). The acquisition includes more than 50 test kits for food allergens, meat and fish speciation, and plant genetics.

2 Dec 2009

FDA grants approval for Dyax' KALBITOR for treating HAE patients

Dyax Corp. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for KALBITOR® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.

2 Dec 2009

Op-eds on World AIDS Day: Research, funding, hunger, Uganda

The "National Institutes of Health - perhaps our best hope for funding a cure for AIDS - has been underfunded since 2003," Kate Krauss, director of the AIDS Policy Project, writes in a Philadelphia Inquirer opinion piece.

1 Dec 2009

Color-coded IV lines with labels to help differentiate multiple lines and avoid errors

Hospitals continue to develop new and improved communications strategies so doctors, nurses and technicians can provide the best patient care. In some hospital wards speed and accuracy are essential - especially the critical care unit / ICU.

1 Dec 2009

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

Ardea Biosciences, Inc. announced positive results from the first dosing group of an ongoing drug-drug interaction and pharmacodynamic study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen). This

1 Dec 2009

Sanofi-Aventis Canada and Intelliject sign license agreement

Sanofi-aventis Canada has announced a licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis) in North America (U.S and Canada).

1 Dec 2009

Intelliject announces an exclusive license with sanofi-aventis for epinephrine auto-injector

Intelliject, Inc. today announced an exclusive license with sanofi-aventis U.S. for a novel epinephrine auto-injector, in the U.S. and Canada territory. Under the license, sanofi-aventis U.S. shall be responsible for manufacturing and commercialization.

1 Dec 2009

Sanofi-aventis, Intelliject sign an exclusive licensing agreement for novel epinephrine auto injector

Sanofi-aventis U.S. announced today the signing of an exclusive licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis) in North America (U.S. and Canada).

30 Nov 2009

Annual Breath of Life Ball to be held at Santa Monica in California

The Asthma & Allergy Foundation of America (AAFA), California Chapter will hold its annual Breath of Life Ball on Tuesday, December 1, 2009 at the elegant Fairmont Miramar Hotel located at 101 Wilshire Blvd., Santa Monica, CA. 90401.

30 Nov 2009

Stallergenes granted European approval to market Oralair

Stallergenes has been granted European approval to market Oralair(R) in both adults and children through a Mutual Recognition Procedure. Germany, the first country where Oralair(R) has been marketed, was the reference Member state.

27 Nov 2009

Low-temperature plasma prototype devices as bactericidal cocktails

MRSA (methicillin-resistant Staphylococcus Aureus) and other drug-resistant bacteria could face annihilation as low-temperature plasma prototype devices have been developed to offer safe, quick, easy and unfailing bactericidal cocktails.

26 Nov 2009

Cells protect themselves against viruses and bacteria with novel non-genetic mechanism

When cells are confronted with an invading virus or bacteria or exposed to an irritating chemical, they protect themselves by going off their DNA recipe and inserting the wrong amino acid into new proteins to defend them against damage, scientists have discovered.

26 Nov 2009

WHO investigates cases of H1N1 drug resistance in U.S., Britain

The WHO is looking into reports that patients with "severely suppressed immune systems" in Britain and the U.S. developed resistance Tamiflu, which is used to treat the symptoms of H1N1 (swine flu), a spokesman for the organization said Tuesday, Reuters reports.

25 Nov 2009

Allergies News and Research

Latest Allergies News and Research

GSK places a batch of AS03 adjuvanted H1N1 vaccine on hold

PRP shows strong potential for accelerated healing of dental implant procedures

Initial positive data from Amira Pharmaceuticals' Phase 1 clinical study of AM461 DP2 antagonist

Cielo MedSolutions, DrFirst partner to provide a comprehensive e-prescribing solution

NIDA funds proposed 'seek and treat' strategy in the fight against HIV/AIDS

NHLBI awards new federal grant to improve the quality of stored transfusion blood

Kalbitor drug approved by FDA

Neogen announces acquisition of BioKits food safety business of San Diego

FDA grants approval for Dyax' KALBITOR for treating HAE patients

Op-eds on World AIDS Day: Research, funding, hunger, Uganda

Color-coded IV lines with labels to help differentiate multiple lines and avoid errors

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

Sanofi-Aventis Canada and Intelliject sign license agreement

Intelliject announces an exclusive license with sanofi-aventis for epinephrine auto-injector

Sanofi-aventis, Intelliject sign an exclusive licensing agreement for novel epinephrine auto injector

Annual Breath of Life Ball to be held at Santa Monica in California

Stallergenes granted European approval to market Oralair

Low-temperature plasma prototype devices as bactericidal cocktails

Cells protect themselves against viruses and bacteria with novel non-genetic mechanism

WHO investigates cases of H1N1 drug resistance in U.S., Britain

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Allergies News and Research

Latest Allergies News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in